News | November 06, 2025
Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New study presents a human-relevant stress model for assessing potential therapeutics
The lab will facilitate the development of herbal and natural-based solutions
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
This marks the fourth acquisition by Corona Remedies from multinational corporations
Subscribe To Our Newsletter & Stay Updated
